Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects - PubMed (original) (raw)
Review
. 2010 May 19;21(5):797-802.
doi: 10.1021/bc100070g.
Affiliations
- PMID: 20397686
- DOI: 10.1021/bc100070g
Review
Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects
Hiroshi Maeda. Bioconjug Chem. 2010.
Abstract
This paper briefly documents the history of the discovery of the EPR (enhanced permeability and retention) effect and elucidates an analogy between bacterial infection involving proteases that trigger kinin generation and cancer. The EPR effect of macromolecules in cancer tissues is defined, and the distinction between the EPR effect (with reference to clearance of macromolecules from the interstitial space of tumor tissues) and the simple passive targeting of drugs to tumors is described. Additional points of discussion include the uniqueness of tumor vessels, the influence of kinin and other vascular mediators such as nitric oxide (NO) and prostaglandins, and the heterogeneity of the EPR effect. Two different strategies to augment the EPR effect that were discovered are elevating blood pressure artificially via slow infusion of angiotensin II and applying nitroglycerin or other NO donors. Use of the nitroagent increased not only the blood flow of the tumor, but also the delivery of drug to the tumor and the drug's therapeutic effect. This finding shows an intriguing analogy to hypoxic cardiac infarct tissue, in that both are improved by NO. These two methods were applied to treatment of rodents and human cancers, in combination with other anticancer agents, with successful results achieved in rodents as well as humans. These data suggest very appealing prospects for utilization of the EPR effect in future development of cancer therapeutics.
Similar articles
- Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H, Bharate GY, Daruwalla J. Maeda H, et al. Eur J Pharm Biopharm. 2009 Mar;71(3):409-19. doi: 10.1016/j.ejpb.2008.11.010. Epub 2008 Dec 3. Eur J Pharm Biopharm. 2009. PMID: 19070661 Review. - Exploiting the enhanced permeability and retention effect for tumor targeting.
Iyer AK, Khaled G, Fang J, Maeda H. Iyer AK, et al. Drug Discov Today. 2006 Sep;11(17-18):812-8. doi: 10.1016/j.drudis.2006.07.005. Drug Discov Today. 2006. PMID: 16935749 Review. - Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H, Fang J, Maeda H. Nakamura H, et al. Expert Opin Drug Deliv. 2015 Jan;12(1):53-64. doi: 10.1517/17425247.2014.955011. Epub 2014 Nov 26. Expert Opin Drug Deliv. 2015. PMID: 25425260 Review. - Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K. Greish K. Methods Mol Biol. 2010;624:25-37. doi: 10.1007/978-1-60761-609-2_3. Methods Mol Biol. 2010. PMID: 20217587 - Tumor delivery of macromolecular drugs based on the EPR effect.
Torchilin V. Torchilin V. Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5. doi: 10.1016/j.addr.2010.03.011. Epub 2010 Mar 18. Adv Drug Deliv Rev. 2011. PMID: 20304019 Review.
Cited by
- Targeted Drug Delivery Strategies for the Treatment of Hepatocellular Carcinoma.
Liu Y, Wu Y, Li Z, Wan D, Pan J. Liu Y, et al. Molecules. 2024 Sep 16;29(18):4405. doi: 10.3390/molecules29184405. Molecules. 2024. PMID: 39339402 Free PMC article. Review. - Extracellular Vesicles as Drug Delivery System for Cancer Therapy.
Wang J, Yin B, Lian J, Wang X. Wang J, et al. Pharmaceutics. 2024 Aug 1;16(8):1029. doi: 10.3390/pharmaceutics16081029. Pharmaceutics. 2024. PMID: 39204374 Free PMC article. Review. - Surface functionalized nanomaterial systems for targeted therapy of endocrine related tumors: a review of recent advancements.
Liu L, Yang M, Chen Z. Liu L, et al. Drug Deliv. 2024 Dec;31(1):2390022. doi: 10.1080/10717544.2024.2390022. Epub 2024 Aug 13. Drug Deliv. 2024. PMID: 39138394 Free PMC article. Review. - A Supramolecular Antibiotic Targeting Drug-Resistant Pseudomonas aeruginosa through the Inhibition of Virulence Factors and Activation of Acquired Immunity.
Jiang C, Zheng L, Yan YJ, Wang M, Liu XJ, Dai JY. Jiang C, et al. ACS Appl Mater Interfaces. 2024 Aug 14;16(32):41828-41842. doi: 10.1021/acsami.4c06665. Epub 2024 Aug 1. ACS Appl Mater Interfaces. 2024. PMID: 39088848 Free PMC article. - Enhancing in situ cancer vaccines using delivery technologies.
Gong N, Alameh MG, El-Mayta R, Xue L, Weissman D, Mitchell MJ. Gong N, et al. Nat Rev Drug Discov. 2024 Aug;23(8):607-625. doi: 10.1038/s41573-024-00974-9. Epub 2024 Jul 1. Nat Rev Drug Discov. 2024. PMID: 38951662 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical